BioSpace News Archive

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics with the potential to modify the course of Parkinson’s disease (“PD”) and related disorders, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent developments.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global spine surgery products market is all set to gather noteworthy amounts in revenues in the forecast period of 2017 to 2025, states the recently published report by Transparency Market Research.

Emerging technologies such as biomarker analysis, digital PCR, NGS, pyrosequencing, or Sanger sequencing, digital microfluidic platforms and advanced molecular phenotyping technologies are expected to thrust the growth of the market.

Addex Therapeutics announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST the same day.

Wilmington, Delaware, United States, Transparency Market Research Inc. – From 2018 to 2026, the market for global liquid biopsy will grow by a substantial value.

In January 2022, Bioretec entered into a supply agreement with Meotec GmbH in Germany for magnesium alloy raw materials for bioresorbable RemeOsTM products.

Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update.

PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update.

Seegene Inc. (KQ096530), South Korea’s leading molecular diagnostics company, today reported first-half (H1) revenue in 2022 of KRW 579.9 billion (USD 445.8 million), down 11 percent year-over-year. Operating profit fell 37 percent to KRW 212.7 billion.